Geron Corporation

Hello, and welcome to General Arm Corporation first quarter 2026 earnings call. At this time, all participants are on listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message as your hand is raised. To withdraw your question, please press star 1-1 again. Please revise that today's conference is pre-recorded. And I turn the call over to Dawn Shotland, Senior Vice President, Investment Relations and Corporate Affairs. You may begin. Dawn Shotland, Senior Vice President, Investment Relations and Corporate Affairs. You may begin.

Dawn Shotland, Senior Vice President, Investment Relations and Corporate Affairs. You may begin. Dawn Shotland, Senior Vice President, Investment Relations and Corporate Affairs. You may begin. Dawn Shotland, Senior Vice President, Investment Relations and Corporate Affairs. You may begin. Dawn Shotland, Senior Vice President, Investment Relations and Corporate Affairs. You may begin. Dawn Shotland, Senior Vice President, Investment Relations and Corporate Affairs. You may begin. Dawn Shotland, Senior Vice President, Investment Relations and Corporate Affairs. You may begin. Dawn Shotland, Senior Vice President, Investment Relations and Corporate Affairs. You may begin. Dawn Shotland, Senior Vice President, Investment Relations and Corporate Affairs. You may begin. Dawn Shotland, Senior Vice President, Investment Relations and Corporate Affairs. You may begin. Dawn Shotland, Senior Vice President, including those relating to our 2026 financial guidance, our current Britello commercialization strategy, and related opportunities in the U.S. and the EU. The therapeutic potential of Britello, other anticipated clinical and commercial events and related timelines, the sufficiency of our financial resources, and other statements that are not historical facts, which of course involve risks and uncertainties that could cause actual events, performance, and results that differ materially from those contained in these forward-looking statements. Therefore, referring to the risk and infirmities described in today's earnings release and under the heading Risk Factors in GERON's most recent periodic report filed with the SEC, which identified important risk factors that could cause actual results to differ materially from those contained in these forward-looking statements and feature updates to GERON's risk and infirmities closures, including its upcoming quarterly report on Form 10Q. GERON undertakes no duty or obligations to update its forward-looking statements. Joining me in today's call are several members of Jerraman's management team, Haruth Kumarjan, Chief Executive Officer, Amit L. Nawabi, our Chief Commercial Officer, Dr. Joseph E., Executive Vice President of Research and Development and Chief Medical Officer, and Michelle Robertson, our Chief Financial Officer. With that, I'll turn the call over to Haruth to review Jerraman's progress and strategy.

Thank you, Dawn, and good morning, everyone. In the first quarter, we made progress on our 2026 strategic priorities. We grew Ritello to focus commercial execution and advance our European commercial and pricing strategy while maintaining our financial security. We also further strengthened our leadership team by welcoming Timothy Williams, our new Chief Legal Officer and Corporate Secretary for Geron, along with two new board members, Patricia Andrews and Konstantin Chinopoulos. Collectively, they bring decades of experience leading and advising buyers of typical companies and will be instrumental as we execute on our strategic priorities and drive commercial growth for RightOwl. RightOwl's first quarter net revenue was $51.8 million, an increase of 31% year-over-year and 8% quarter-over-quarter, placing us on track to achieve our 2026 net revenue guidance $220 million, $240 million. We continue to see strong tailwinds in the treatment landscape, complementing our refocused commercial strategy and driving Ritello demand. We are focused on three key initiatives fueling our Ritello U.S. growth strategy. On the commercial side, we're continuing to increase awareness and education for Ritello amongst U.S. healthcare professionals with a refined engagement plan to help identify appropriate second-line patients faster, and complementing our field-force efforts by increasing our in-person and digital presence across hematology forums through accelerated investment in our surround sound approach. From a medical affairs perspective, we are expanding our research partnerships and investigator-sponsored trial program with the U.S. Hematology Community to increase our knowledge and real-world experience with Ritello. Growing Ritello demand in the U.S. market remains our priority, and we know from patients at ECTD there is an unmet need for low-risk MDS treatment options in Europe and an interest in Ritello to help address that need. This quarter, we engaged in conversations with European medical experts made progress with health technology assessment, and conducted detailed research to better understand the European pricing environment. As a biotech company, we have an obligation to make our medicines available to patients, but we also have the responsibility to maintain a value that reflects our innovation and supports our next wave of growth. We know the demand in Europe for Ritello is real, and we are exploring the latest commercial strategy that could maximize Rattel's values while maintaining its pricing integrity in the U.S. We expect to communicate our commercial plans for Europe before the end of the year, once we have clarity on pricing and market opportunities. Financial discipline remains another top priority for Gerald. We reported total operating expenses for the first quarter of $50.4 million, down about 9% year over year, a testament to our financial business. A few first quarter dynamics, such as annual bonus, severance from last year's restructuring, and CNC investments to strengthen our supply chain for Ritello led to a decrease in cash, which was in line with our expectations. We are on track to achieve our 2026 total operating expenses of $230 million to $240 million. With that, I'll turn it over to Nawawi to provide more detail on Ritello's commercial performance and execution.